These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32756110)

  • 1. Sero-survey of polio antibodies and quality of acute flaccid paralysis surveillance in Chongqing, China: A cross-sectional study.
    Xu J; Kuang S; Rong R; Zhang Y; Tang W; Wang Q
    Medicine (Baltimore); 2020 Jul; 99(31):e21298. PubMed ID: 32756110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological serosurvey of poliovirus in Guangdong, China: A cross-sectional study.
    Tan Q; Zhu Q; Zheng H; Zhang B; Wu C; Guo X; Li H; Liu L; Liu Y; Rutherford S; Zheng H
    Hum Vaccin Immunother; 2018; 14(11):2644-2648. PubMed ID: 30059644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey.
    Xu J; Wang Q; Kuang S; Rong R; Zhang Y; Fu X; Tang W
    Hum Vaccin Immunother; 2021 Jul; 17(7):2125-2131. PubMed ID: 33759702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity status against poliomyelitis in young migrants: a seroprevalence study.
    Veronesi L; Colucci ME; Capobianco E; Bracchi MT; Zoni R; Palandri L; Affanni P
    Acta Biomed; 2019 Sep; 90(9-S):28-34. PubMed ID: 31517887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population immunity to polioviruses in the context of a large-scale wild poliovirus type 1 outbreak in Tajikistan, 2010.
    Khetsuriani N; Pallansch MA; Jabirov S; Saparova N; Oberste MS; Wannemuehler K; Ursu P; Wassilak S; Martin R
    Vaccine; 2013 Oct; 31(42):4911-6. PubMed ID: 23891502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine.
    Hendry AJ; Beard FH; Dey A; Quinn H; Hueston L; Dwyer DE; McIntyre PB
    Vaccine; 2020 Mar; 38(11):2572-2577. PubMed ID: 32037225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poliovirus neutralizing antibody levels among individuals in three regions of Ghana.
    Opare JK; Akweongo P; Afari EA; Odoom JK
    Ghana Med J; 2019 Jun; 53(2):170-180. PubMed ID: 31481814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people.
    Kim HJ; Hwang S; Lee S; Kwon Y; Park K; Park YJ; Bae GR; Lee SW; Jeong YS; Hyeon JY
    BMC Infect Dis; 2015 Mar; 15():164. PubMed ID: 25881203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan.
    Habib M; Soofi S; Ali N; Sutter RW; Palansch M; Qureshi H; Akhtar T; Molodecky NA; Okayasu H; Bhutta ZA
    Vaccine; 2013 Apr; 31(15):1987-93. PubMed ID: 23429005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poliovirus immunity among pregnant females aged 15-44 years, Namibia, 2010.
    Cardemil CV; Jonas A; Gerber S; Weldon WC; Oberste MS; Beukes A; Sawadogo S; Patel SV; Zeko S; Muroua C; Gaeb E; Wannemuehler K; Goodson JL
    J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S136-42. PubMed ID: 25316828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of anti-polio antibodies in children from polio high risk area of Afghanistan: A cross sectional survey 2017.
    Hussain I; Mach O; Hamid NA; Bhatti ZS; Moore DD; Oberste MS; Khan S; Khan H; Weldon WC; Sutter RW; Bhutta ZA; Soofi SB
    Vaccine; 2018 Apr; 36(15):1921-1924. PubMed ID: 29510918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of seroprevalence against poliovirus among Italian adolescents and adults.
    Lupi S; Stefanati A; Baldovin T; Roman A; Baldo V; Gabutti G
    Hum Vaccin Immunother; 2019; 15(3):677-682. PubMed ID: 30427738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of poliovirus antibodies in Nigeria: refining strategies to sustain the eradication effort.
    Bolu O; Adamu U; Franka R; Umeokonkwo CD; An Q; Greby S; McDonald S; Mainou B; Mba N; Agala N; Archer WR; Braka F; Etapelong SG; Gashu TS; Siddique AR; Asekun A; Okoye M; Iriemenam N; Wiesen E; Swaminathan M; Ihekweazu C; Shuaib F
    Pan Afr Med J; 2023; 45(Suppl 2):2. PubMed ID: 38370104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa.
    Guindo O; Mach O; Doumbia S; Ekra DK; Beavogui AH; Weldon WC; Oberste MS; Sutter RW
    Vaccine; 2018 Feb; 36(8):1027-1031. PubMed ID: 29358054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency of immunity to poliovirus type 3: a lurking danger?
    Reinheimer C; Friedrichs I; Rabenau HF; Doerr HW
    BMC Infect Dis; 2012 Jan; 12():24. PubMed ID: 22280025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological investigation on the prevalence of poliovirus in Guangdong province: A cross-sectional study.
    Chen L; Qiu Q; Zhu Q; Li J; Xie X; Shao X; Liang J; Zhang W; Zheng H; Li B; Xu L; Zeng H; Sun L
    Hum Vaccin Immunother; 2024 Dec; 20(1):2300156. PubMed ID: 38189143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An epidemiological analysis of Acute Flaccid Paralysis (AFP) surveillance in Kenya, 2016 to 2018.
    Tesfaye B; Sowe A; Kisangau N; Ogange J; Ntoburi S; Nekar I; Muitherero C; Camara Y; Gathenji C; Langat D; Sergon K; Limo H; Nzunza R; Kiptoon S; Kareko D; Onuekwusi I
    BMC Infect Dis; 2020 Aug; 20(1):611. PubMed ID: 32811467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of Anti-polio Antibodies in Children From Polio High-risk Areas of Pakistan: A Cross-Sectional Survey 2015-2016.
    Hussain I; Mach O; Habib A; Bhatti Z; Suhag Z; Oberste MS; Weldon WC; Sutter RW; Soofi SB; Bhutta ZA
    Pediatr Infect Dis J; 2017 Sep; 36(9):e230-e236. PubMed ID: 28806355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poliovirus Type 2 Seroprevalence Following Full- or Fractional-Dose Inactivated Poliovirus Vaccine in the Period After Sabin Type 2 Withdrawal in Sri Lanka.
    Gamage D; Mach O; Ginige S; Weldon WC; Oberste MS; Jeyaseelan V; Sutter RW
    J Infect Dis; 2019 May; 219(12):1887-1892. PubMed ID: 30649505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine-associated paralytic poliomyelitis and other diseases with acute flaccid paralysis syndrome in Belarus.
    Samoilovich EO; Feldman EV; Yermalovich MA; Protas II; Titov LP
    Cent Eur J Public Health; 2003 Dec; 11(4):213-8. PubMed ID: 14768785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.